Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Alflutinib |
Synonyms | |
Therapy Description |
Alflutinib (AST2818) is a third-generation EGFR inhibitor that targets both EGFR activating mutations and T790M, potentially leading to tumor growth inhibition (J Thorac Oncol. Nov 2017, Vol 12, Issue 11, Suppl. 2, pS2138, PMID: 33780662, PMID: 35662408). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Alflutinib | AST2818|AST2818|furmonertinib | EGFR Inhibitor 3rd gen 25 | Alflutinib (AST2818) is a third-generation EGFR inhibitor that targets both EGFR activating mutations and T790M, potentially leading to tumor growth inhibition (J Thorac Oncol. Nov 2017, Vol 12, Issue 11, Suppl. 2, pS2138, PMID: 33780662, PMID: 35662408). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05607550 | Phase III | Alflutinib | Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05364073 | Phase I | Alflutinib | Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Activating EGFR or HER2 Mutations | Recruiting | USA | ITA | FRA | ESP | CAN | 6 |